Latest Breaking News On - Chief executive officer sekar kathiresan - Page 1 : comparemela.com

Initial data from a human clinical trial suggests an experimental drug from Verve Therapeutics that uses gene editing to permanently lower cholesterol raises hopes that people can one day trade daily lipid-lowering pills for a one-time treatment

United statesDonald lloyd jonesSekar kathiresanNorthwestern universityDrug administrationAmerican heart associationVerve therapeuticsChief executive officer sekar kathiresanClinical drug trialExperimental drug